About Cambium

Cambium Medical Technologies (“Cambium” or “the Company”) was founded in 2013 by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA).  The Company is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular® a standardized, commercialized platelet derived biologic eye drop for dry eye (keratoconjunctivis sicca) as its first FDA approved therapy.  Elate Ocular® is an investigational drug and is not yet approved for sale in or outside the United States. A Phase I/II FDA dry eye clinical study is underway at several U.S. sites to assess the safety and exploratory efficacy of Elate Ocular® among patients with a severe form of dry eye.

Since 2015 Cambium has commercialized through a strategic partner (Zheng Yang Biomedical Technology Co LTD, Taipei, Taiwan) the Company’s novel processed platelets (Aurarix®) in its partner’s line of UltraGRO™ stem cell growth supplements.  Cambium remains committed to pursuing added applications of its Aurarix® novel platelets either directly or through strategic partners. For more information or to contact Cambium, please click on this link.

Our Mission

“Using Novel Processed Platelets to Improve Patients' Quality of Life...from Within”

Cambium Milestones

June 2011 through June 2012

Three core patents filed with US PTO

June 2012 through October 2014

Seven additional (foreign) patents filled

October 2012

First successful FDA pre-IND meeting on Elate Ocular®

July 2013

Cambium incorporated as a Georgia LLC

August 2013

CEO with prior ophthalmic, blood industry and start-up expertise joins Cambium

May 2014

Secured strategic partner and sub-license with Zheng Yang Biomedical Technology Co LTD, Taipei, Taiwan for commercialization of Aurarix® in worldwide cell growth supplement market

May 2014

Secured worldwide technology License from Emory University for all fields of use

September 2014

Third party reimbursement specialist concludes in White Paper Elate Ocular® “should be able to obtain [reimbursement] coverage including preferred formulary status”

October 2014

Cambium Medical Monitor, two ophthalmic clinical/regulatory consultants & seven member key industry dry eye opinion leaders Medical Advisory Board (MAB) established

October 2014

Elate Ocular and Aurarix trademarks filed with US PTO for Cambium’s dry eye and novel human platelet products respectfully

November 2014

Second successful FDA pre-IND meeting on Elate Ocular® with emphasis on CMC section of upcoming IND

November 2014

Selected and presented at SEBIO Investor Conference, (Atlanta, Georgia) as Early Stage Company

Fall 2014

Standardized manufacturing process finalized, successfully transferred to strategic partner for use in production of Aurarix® for stem cell growth supplement market

December 2014

Atlanta Aurarix® manufacturing start-up begins

March 2015

First sale of Aurarix® as UltraGRO-Advanced™ occurs through strategic partner

April 2015

First Cambium revenues (royalties from partner) begin

April 2015

MAB convened to finalize Elate Ocular® dry eye FDA clinical trial protocol

April, May 2015

Two patents filed on novel dry eye packaging developed by Georgia Tech graduate bioengineering students

May 2015

US FDA clinical sites and Principal Investigators for Elate Ocular® clinical trials identified

June 2015

Cambium selected as presenting company at New York Venture Summit, NYC

July 2015

Three future clinical study sites subsequently rated in “top 10” of all US ophthalmology hospital sites by US News and World Report and with all sites receiving votes

September 2015

Notice of Allowance of NIH STTR grant award

November 2015

Cambium selected as presenting company at SEBIO & GABIO investor conferences

September 2016

Cambium selected as presenting company at Tear Film & Ocular Surface Society’s bi-annual conference, Montpellier, FR

December 2016

Cambium selected as presenting company at New England Investor Summit, Boston MA

May 2017

Cambium closes $1.75 million interim financing

August 2017

Cambium submits IND for Ph I/II dry eye study to FDA

October 2017

Notice of allowance from FDA that Cambium’s Phase I/II dry eye study can start

November 2017

Successful tech transfer, mfg start-up at CMO for FDA study product supply

December 2017

Neera Jagirdar, MD joins Cambium as Mgr-Clinical & Regulatory Affairs

January 2018

Cambium moves into new Atlanta HQ offices

May 2018

Cambium closes $5 million Series A financing

May 2018

1st patient enrolled in Phase I/II dry eye study

October 2018

2nd generation Elate Ocular® development initiated

February 2019

Victor Perez, MD (Duke Eye Center, Durham, NC), a distinguished corneal specialist and opinion leader, joins Cambium’s Medical Advisory Board

February 2019

Cambium selected as presenting company at Venture Summit West, San Francisco, CA